Getinge invites fund managers, analysts, and media to Q1 Report 2026 conference call

Getinge will publish its Q1 2026 report on April 21, 2026 at 12:00 p.m. CEST and hold a conference call at 13:00 CEST hosted by CEO Mattias Perjos and CFO Agneta Palmér. Fund managers, analysts and media can register for teleconference access (telephone numbers and conference ID provided after registration) and will be able to ask questions verbally during the call.

Analysis

The upcoming report is an information catalyst that will likely re-price Getinge on two vectors: near-term execution (orders, backlog conversion, working capital) and medium-term structural trends (service/aftermarket mix, hospital capex). Because service revenues typically carry 2x+ gross margins vs new equipment, any commentary showing durable service growth or higher attach rates would mechanically lift margins over 3–6 quarters even if new equipment unit demand stays soft. Conversely, signs of higher distributor inventory or elongated hospital procurement cycles would depress revenue visibility and force further margin compression through underutilized fixed costs.

Currency and reimbursement commentary will act as a second-order lever. A weaker SEK versus USD/EUR can inflate reported SEK sales and mask underlying demand weakness in dollar terms; management comments on pricing and tender timing will therefore be more informative than headline FX-adjusted revenue. Regulatory or product-specific issues (sterilization/OR integration lines) would create outsized P&L volatility because remediation costs show up immediately while order recovery spreads over years.

Event dynamics favor volatility trades around the print but set a clear medium-term horizon for conviction: if the call confirms backlog stability + improving attach rates, expect a 20–40% re-rate over 3–9 months as margin mix normalizes; if it confirms order deterioration and working-capital stress, downside of similar magnitude is plausible as market reprices through multiple compression and restructuring risk. Watch free cash flow conversion and explicit CAPEX/tender phasing language — those sentences will determine whether this is an execution or demand problem and set the path for the next 6–18 months.

Key Decisions for Investors

• Event-volatility play (near-term): Buy an at-the-money straddle on GETI-B (Nasdaq Stockholm) expiring June 2026 sized to <1% fund NAV to capture an expected 20–40% directional move; cap premium risk and take profits or cut if implied vol compresses >40% post-release.
• Pair trade (3–9 months): Long GETI-B vs short SYK (Stryker) 1:0.6 if the call confirms service mix improvement — targets +30% on GETI-B and -10% on SYK; stop-loss for GETI-B at -12% absolute if FCF conversion guidance is cut.
• Protective hedge (6–12 months): If already long GETI-B equity, buy 3–6 month put spreads (e.g., buy 15% OTM put / sell 30% OTM put) to limit downside to ~10–12% cost while retaining upside; use this if management messaging is unclear on backlog conversion.
• Short catalyst trade (3–12 months): Initiate a tactical short GETI-B if the report shows widening working capital and slowed tender wins — target 25–35% downside; size modestly (<=1.5% NAV) because execution risk and potential for quick rebounds post-guidance are high.